Shenzhen Chipscreen Biosciences 将来の成長

Future 基準チェック /26

Shenzhen Chipscreen Biosciences利益と収益がそれぞれ年間64.9%と28.6%増加すると予測されています。EPS は年間増加すると予想されています。自己資本利益率は 3 年後に-0.9% 64.7%なると予測されています。

主要情報

64.9%

収益成長率

64.7%

EPS成長率

Pharmaceuticals 収益成長	18.8%
収益成長率	28.6%
将来の株主資本利益率	-0.9%
アナリストカバレッジ	Low
最終更新日	30 Oct 2024

今後の成長に関する最新情報

更新なし

Recent updates

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

Oct 08

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

Aug 21

We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

Jun 04

Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

Apr 24

Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Apr 05

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Mar 06

業績と収益の成長予測

SHSE:688321 - アナリストの将来予測と過去の財務データ ( )CNY Millions
日付	収益	収益	フリー・キャッシュフロー	営業活動によるキャッシュ	平均アナリスト数
12/31/2026	1,224	11	N/A	143	1
12/31/2025	938	-80	N/A	77	1
12/31/2024	705	-160	N/A	48	1
9/30/2024	656	-70	-188	29	N/A
6/30/2024	584	-108	-217	-20	N/A
3/31/2024	548	103	-293	-73	N/A
12/31/2023	524	89	-386	-157	N/A
9/30/2023	543	168	-358	-70	N/A
6/30/2023	556	192	-357	-101	N/A
3/31/2023	532	-11	-403	-17	N/A
12/31/2022	530	17	-357	43	N/A
9/30/2022	490	4	-381	70	N/A
6/30/2022	463	10	-312	130	N/A
3/31/2022	460	26	-180	112	N/A
12/31/2021	430	22	-164	125	N/A
9/30/2021	360	-32	-215	74	N/A
6/30/2021	342	-5	-231	54	N/A
3/31/2021	312	19	-219	90	N/A
12/31/2020	269	31	-243	94	N/A
9/30/2020	231	37	-185	91	N/A
6/30/2020	202	31	-201	36	N/A
3/31/2020	181	23	-201	-6	N/A
12/31/2019	174	19	-158	-25	N/A
9/30/2019	181	37	-130	-16	N/A
6/30/2019	157	31	N/A	N/A	N/A
3/31/2019	142	28	-91	40	N/A
12/31/2018	148	31	-118	23	N/A
12/31/2017	111	24	N/A	3	N/A
12/31/2016	85	5	N/A	60	N/A

アナリストによる今後の成長予測

収入対貯蓄率: 688321今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 688321今後 3 年間、利益が出ない状態が続くと予測されています。

高成長収益: 688321今後 3 年間、利益が出ない状態が続くと予測されています。

収益対市場: 688321の収益 ( 28.6% ) CN市場 ( 13.9% ) よりも速いペースで成長すると予測されています。

高い収益成長: 688321の収益 ( 28.6% ) 20%よりも速いペースで成長すると予測されています。

一株当たり利益成長率予想

将来の株主資本利益率

将来のROE: 688321 3 年以内に赤字になると予測されています。

Shenzhen Chipscreen Biosciences 将来の成長

Future 基準チェック /26

主要情報

今後の成長に関する最新情報

Recent updates

Shenzhen Chipscreen Biosciences Co., Ltd. announced that it expects to receive CNY 960 million in funding

Shenzhen Chipscreen Biosciences Co., Ltd. and Chengdu Chipscreen Pharmaceutical Ltd. Receives Drug Clinical Trial Approval Notice Approval Notice for Phase III Clinical Trials

New major risk - Financial position

Third quarter 2024 earnings released: CN¥0.025 loss per share (vs CN¥0.12 loss in 3Q 2023)

Shenzhen Chipscreen Biosciences Co., Ltd. Submits Investigational New Drug Application for CS231295 Tablets

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) 50% Price Boost Is Out Of Tune With Revenues

New minor risk - Share price stability

Shenzhen Chipscreen Biosciences Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Price In Tune With Revenues

Shenzhen Chipscreen Biosciences Co., Ltd. to Report First Half, 2024 Results on Aug 16, 2024

We Think Shenzhen Chipscreen Biosciences (SHSE:688321) Has A Fair Chunk Of Debt

National Medical Products Administration Approves Chipscreen Biosciences Co., Ltd.'s Chidamide Combined with R-CHOP for the Treatment of Diffuse Large B-Cell Lymphoma

First quarter 2024 earnings released: CN¥0.045 loss per share (vs CN¥0.08 loss in 1Q 2023)

Investors Appear Satisfied With Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Prospects As Shares Rocket 26%

New major risk - Revenue and earnings growth

Solid Earnings May Not Tell The Whole Story For Shenzhen Chipscreen Biosciences (SHSE:688321)

Full year 2023 earnings: EPS and revenues miss analyst expectations

Shenzhen Chipscreen Biosciences Co., Ltd., Annual General Meeting, Apr 19, 2024

Shenzhen Chipscreen Biosciences Co., Ltd. to Report Q1, 2024 Results on Apr 29, 2024

Shenzhen Chipscreen Biosciences Co., Ltd. (SHSE:688321) commences an Equity Buyback Plan for CNY 15 million worth of its shares, under the authorization approved on February 22, 2024.

Shenzhen Chipscreen Biosciences Co., Ltd. Announces Positive Results from Phase II Clinical Trial (CGZ203 Study) of Chiglitazar Monotherapy for Non-Alalcoholic Steatohepatitis

Shenzhen Chipscreen Biosciences Co., Ltd.'s (SHSE:688321) Shares Climb 30% But Its Business Is Yet to Catch Up

Full year 2023 earnings: EPS and revenues miss analyst expectations

Investor sentiment deteriorates as stock falls 24%

Third quarter 2023 earnings released: CN¥0.12 loss per share (vs CN¥0.056 loss in 3Q 2022)

New minor risk - Share price stability

Shenzhen Chipscreen Biosciences Co., Ltd. to Report First Half, 2023 Results on Aug 12, 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Full year 2022 earnings released: EPS: CN¥0.043 (vs CN¥0.054 in FY 2021)

Now 20% undervalued

Less than half of directors are independent

Third quarter 2022 earnings released: CN¥0.056 loss per share (vs CN¥0.042 loss in 3Q 2021)

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Third quarter 2021 earnings released: CN¥0.042 loss per share (vs CN¥0.024 profit in 3Q 2020)

First quarter 2021 earnings released: CN¥0.018 loss per share (vs CN¥0.013 profit in 1Q 2020)

Full year 2020 earnings released: EPS CN¥0.076 (vs CN¥0.052 in FY 2019)

Shenzhen Chipscreen Biosciences Co., Ltd. Announces Voluntary Disclosure of Application for Clinical Trial Accepted

Full year 2020 earnings released: EPS CN¥0.076 (vs CN¥0.052 in FY 2019)

Revenue beats expectations, earnings disappoint

New 90-day low: CN¥33.79

Shenzhen Chipscreen Biosciences Co., Ltd. Submits Its Pivotal Phase III Clinical Trial Application of National Class I Innovative Drug Chiauranib

New 90-day low: CN¥36.33

Shenzhen Chipscreen Biosciences Co., Ltd. Announces CDE "Breakthrough Therapy Designation"

New 90-day low: CN¥39.35

CHIPSCREEN and HISUN Reach A Strategic Cooperation

New 90-day low: CN¥44.13

New 90-day low: CN¥45.51

New 90-day low - CN¥49.02

First half earnings released

業績と収益の成長予測

アナリストによる今後の成長予測

一株当たり利益成長率予想

将来の株主資本利益率

成長企業の発掘